Prolacta Formula Fortifier Starts Trial For Newborns With Rare Heart Condition
This article was originally published in The Rose Sheet
Executive Summary
Prolacta Bioscience developed human milk-based formula fortifier for full-term infants born with conditions that make them vulnerable to nutrition deficiencies. Pending results from research at 12 US hospitals, the product would roll out commercially in 2018.
You may also be interested in...
Updated Infant Formula Regs Raise Quality Control Bar
Beginning in July 2014 manufacturers must test infant formulas for salmonella and cronobacter before distribution, according to an IFR and guidances FDA released Feb. 6. The rule also requires firms to prove formula meets quality standards including providing all necessary nutrients and appropriate levels of protein.
Revlon Gains $1.4Bn Financing From Subsidiaries, Appoints Interim CFO Amid Bankruptcy Fallout
Revlon approved for $1.4bn debtor-in-possession financing from BrandCo Lenders, a group of operating subsidiaries formed in capital structure changes which owns much of Revlon’s intellectual property. Firm appoints interim CFO to set course for debt restructuring.
E.l.f. Hoists 2023 Full-Year Sales Guidance As Value Prices Attract New Customers
E.l.f. Beauty’s sales grew 26% to $122.6m in the fiscal 2023 first quarter, leading the Oakland, CA-based firm to increase full-year projections. According to company leadership, e.l.f. is capturing market share at a rapid clip while expanding distribution, notably in pharmacy retail.